Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Salt Lake City, UT
NPI: 1427008341Primary Practice Location
UNIVERSITY OF UTAH HOSPITAL AND CLINICS
1950 Circle Of Hope Dr, Salt Lake City, UT
Primary Employer
Spanish Valley Clinic
sanjuanhealth.org
HQ Phone
Get M.D. Josef's Phone Numberphone_androidMobile
Get M.D. Josef's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
UT State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 41 | 85 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 25 | 44 |
High altitude genetic adaptation in Tibetans: no role of increased hemoglobin-oxygen affinity.
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
Authors: Tariq Mughal, Ruben Mesa, Raajit Rampal
Publication Date: 2014-10-21
Authors: Kapralova, Katarina, Lanikova, Lucie, Lorenzo, Felipe, Song, Jihyun, Horvathova, Monika, Divoky, Vladimir, Prchal, Josef T
Journal: Blood
Publication Date: 2013-12-02
Lead Sponsor: John Mascarenhas
Collaborators: Roche Pharma AG, The Leukemia and Lymphoma Society
Intervention / Treatment: DRUG: Pegasys, DRUG: RG7388
Lead Sponsor: John Mascarenhas
Collaborators: National Cancer Institute (NCI), Incyte Corporation, Myeloproliferative Disorders-Research Consortium
Intervention / Treatment: DRUG: Decitabine, DRUG: Ruxolitinib
Lead Sponsor: John Mascarenhas
Collaborators: National Cancer Institute (NCI), Novartis, Incyte Corporation, Myeloproliferative Disorders-Research Consortium
Intervention / Treatment: DRUG: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)